Palo Alto Investors’s Aclaris Therapeutics ACRS Stock Holding History

Palo Alto Investors’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.05M	Buy	1,613,430 +46,590	+3%	+$157K	0.93%	28
2025 Q4	$4.72M	Hold	1,566,840	–	–	0.66%	30
2025 Q3	$2.98M	Buy	1,566,840 +176,812	+13%	+$308K	0.55%	28
2025 Q2	$1.97M	Buy	1,390,028 +614,000	+79%	+$831K	0.42%	29
2025 Q1	$1.19M	Buy	776,028 +206,196	+36%	+$440K	0.23%	34
2024 Q4	$1.41M	Hold	569,832	–	–	0.22%	32
2024 Q3	$655K	Hold	569,832	–	–	0.09%	40
2024 Q2	$627K	Hold	569,832	–	–	0.07%	37
2024 Q1	$707K	Buy	+569,832	New	+$680K	0.08%	37

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Palo Alto Investors's ACRS Position: Q1 2026 in Review

Palo Alto Investors increased its Aclaris Therapeutics (ACRS) stake by 3% in Q1 2026, buying an estimated $157K and bringing the position to 1,613,430 shares worth $6.05M. The position accounts for 0.93% of the portfolio, ranked #28.

Palo Alto Investors first reported a position in ACRS in Q1 2024 and has held it in 9 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

Palo Alto Investors held 1,613,430 shares of Aclaris Therapeutics worth $6.05M as of Q1 2026.
Palo Alto Investors bought 46,590 Aclaris Therapeutics shares in Q1 2026, an estimated $157K.
Aclaris Therapeutics made up 0.93% of Palo Alto Investors's portfolio in Q1 2026, its #28 holding.
Palo Alto Investors first reported a position in Aclaris Therapeutics in Q1 2024 and has held it in 9 quarters since.
136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.